SCHEMBL4394067

SCHEMBL4394067

CC(C)(C)OC(=O)NCCCNC(=S)Nc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
MAPT P10636 3/20 0.55
GAA P10253 1/20 0.54
MAPK1 P28482 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
PLA2G1B P04054 1/20 0.52
ATG4B Q9Y4P1 1/20 0.52
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.48
EPHX2 P34913 2/20 0.48
ACHE P22303 1/20 0.48
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MEN1 O00255 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
CXCR2 P25025 2/20 0.46
TRPV1 Q8NER1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4396949 0.86 KMT2A (0.64) LMNAMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL5100819 0.83 ALDH1A1 (0.51) LMNAMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL4392250 0.83 KMT2A (0.54) LMNAMAPTGAAL3MBTL1SMN1; SMN2
SCHEMBL5097622 0.82 ALDH1A1 (0.50) LMNAMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL23389249 0.82 CA1 (0.55) LMNAGAAL3MBTL1SMN1; SMN2KDM4E
SCHEMBL31300041 0.82 ALDH1A1 (0.59) LMNAMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL4402193 0.81 CYP17A1 (0.49) LMNAGAASMN1; SMN2CA1CA2
SCHEMBL4396662 0.80 KMT2A (0.54) LMNAMAPTGAAL3MBTL1SMN1; SMN2
SCHEMBL4398802 0.80 GAA (0.43) LMNAGAAMAPK1SMN1; SMN2KDM4E
SCHEMBL3427239 0.79 EPHX2 (0.65) LMNAMAPTGAAL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1300401-B1 THIAZOLE DERIVATIVES FOR USE AS ANTIINFLAMMATORIES DAINIPPON SUMITOMO PHARMA CO (JP) 2009-12-09 EP disclosed
US-7396842-B2 Five-membered cyclic compounds DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-08 US disclosed
EP-1669070-A2 2-imino-thiazolidine and -oxazolidine derivatives for use as antiinflammatory agents Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-06-14 EP disclosed
US-20050222226-A1 Five-membered cyclic compounds SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2005-10-06 US disclosed
US-6919361-B2 Five-membered-ring compound SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-07-19 US disclosed
US-20040072827-A1 Five-membered-ring compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2004-04-15 US disclosed
EP-1300401-A1 FIVE-MEMBERED-RING COMPOUND SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072827-A1 Five-membered-ring compound EPX, IL5, CCR9 LMNA 4315/4885MAPT 4768/4885GAA 4650/4885
US-20050222226-A1 Five-membered cyclic compounds EPX, CCL11, CCR9 LMNA 3956/4885MAPT 4705/4885GAA 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.